PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

The following is an excerpt from Passionate Outlier: Gay Writers and Allies on Their Work by Frank Pizzoli and now available from Rebel Satori Press. Subscribe to our newsletter for a refreshing ...

Keytruda and Padcev combination improved survival in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy. The KEYNOTE-905 trial showed significant event-free survival ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

Matthew Herper covers medical innovation — both its promise and its perils. Pfizer said Tuesday that its antibody-drug conjugate Padcev extended survival when combined with the cancer immunotherapy ...

Vidal rushed six times for 16 yards while failing to bring in his lone target in Sunday's 27-13 preseason win over the Saints. Vidal got the first crack at touches out of the backfield Sunday with ...

The Braves have claimed infielder Vidal Bruján off waivers from the Orioles, according to announcements from both clubs. Bruján had not been designated for assignment by the Orioles but it appears ...

The Orioles have claimed infielder Vidal Brujan off waivers from the Cubs and right-hander Carson Ragsdale off waivers from the Giants, according to a team announcement. Brujan is out of options and ...

Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will cut administrative, ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will cut ...